JP2003500450A - 陽電子放射断層撮影法のための表皮成長因子受容体に結合する新規化合物 - Google Patents

陽電子放射断層撮影法のための表皮成長因子受容体に結合する新規化合物

Info

Publication number
JP2003500450A
JP2003500450A JP2000620961A JP2000620961A JP2003500450A JP 2003500450 A JP2003500450 A JP 2003500450A JP 2000620961 A JP2000620961 A JP 2000620961A JP 2000620961 A JP2000620961 A JP 2000620961A JP 2003500450 A JP2003500450 A JP 2003500450A
Authority
JP
Japan
Prior art keywords
compound
group
fluorine
hydrogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000620961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500450A5 (enExample
Inventor
イヤル ミシャニ，
トマス ボナセラ，
ジュゼピナ オルトゥ，
ユリア ロゼン，
アヴィヴ ガゼィト，
アレグザンダー レヴィツキ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Publication of JP2003500450A publication Critical patent/JP2003500450A/ja
Publication of JP2003500450A5 publication Critical patent/JP2003500450A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2000620961A 1999-06-01 2000-05-19 陽電子放射断層撮影法のための表皮成長因子受容体に結合する新規化合物 Pending JP2003500450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/322,979 1999-06-01
US09/322,979 US6126917A (en) 1999-06-01 1999-06-01 Epidermal growth factor receptor binding compounds for positron emission tomography
PCT/US2000/013749 WO2000072849A1 (en) 1999-06-01 2000-05-19 Novel epidermal growth factor receptor-binding compounds for positron emission tomography

Publications (2)

Publication Number Publication Date
JP2003500450A true JP2003500450A (ja) 2003-01-07
JP2003500450A5 JP2003500450A5 (enExample) 2007-05-10

Family

ID=23257276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000620961A Pending JP2003500450A (ja) 1999-06-01 2000-05-19 陽電子放射断層撮影法のための表皮成長因子受容体に結合する新規化合物

Country Status (7)

Country Link
US (1) US6126917A (enExample)
EP (1) EP1180034A4 (enExample)
JP (1) JP2003500450A (enExample)
AU (1) AU4857400A (enExample)
CA (1) CA2375826A1 (enExample)
IL (1) IL146805A0 (enExample)
WO (1) WO2000072849A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007191430A (ja) * 2006-01-19 2007-08-02 Fujifilm Ri Pharma Co Ltd ４−フェノキシキナゾリン誘導体放射性化合物
JP2011508752A (ja) * 2008-01-03 2011-03-17 コミッサリア ア ロンネルジー アトミック エ オ ゾンネルジー ザルテルナティーフ マークされたプリン誘導体の製造方法、該プリン誘導体、およびその使用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508343A (ja) * 2000-09-07 2004-03-18 ウイスコンシン　アラムニ　リサーチ　ファンデーション １７ｆ標識フルオロアルカンの合成
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1482983A4 (en) * 2001-06-14 2006-07-12 Yissum Res Dev Co NON-MYELOABLATIVE AND TOLEROGENIC TREATMENT BY TYRPHOSTINES
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
CA2533345A1 (en) * 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
BRPI0414532B1 (pt) * 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
NO20035682D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
NO20035681D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av lungekreft
AU2006217738A1 (en) * 2005-02-26 2006-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) * 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2010012442A (es) * 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8753605B2 (en) 2010-08-31 2014-06-17 The Board Of Trustees Of The Leland Stanford Junior University Imaging probes, methods of making imaging probes, and methods of imaging
CN103254140B (zh) * 2012-02-17 2016-02-17 北京师范大学 新型18f标记取代喹唑啉类化合物及其制备方法和肿瘤pet显像应用
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05208911A (ja) * 1991-06-28 1993-08-20 Imperial Chem Ind Plc <Ici> 抗癌作用を有する医薬組成物、キナゾリン誘導体及びその製法
JPH0673025A (ja) * 1992-06-26 1994-03-15 Zeneca Ltd キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
WO1995015758A1 (en) * 1993-12-10 1995-06-15 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase
WO1997030035A1 (en) * 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1998010767A2 (en) * 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP2002516823A (ja) * 1998-05-28 2002-06-11 パーカー ヒューズ インスティテュート 脳腫瘍の治療のためのキナゾリン
JP2002521475A (ja) * 1998-07-30 2002-07-16 パーカー ヒューズ インスティテュート 脂質を低下するキナゾリン誘導体
JP2002523403A (ja) * 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
JP2002539262A (ja) * 1999-03-19 2002-11-19 パーカー ヒューズ インスティテュート キナゾリン化合物製剤および治療におけるその使用
JP2002540103A (ja) * 1999-03-19 2002-11-26 パーカー ヒューズ インスティテュート キナゾリン類およびそれらの治療上における使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144266A (en) * 1981-03-04 1982-09-06 Sankyo Co Ltd 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH05208911A (ja) * 1991-06-28 1993-08-20 Imperial Chem Ind Plc <Ici> 抗癌作用を有する医薬組成物、キナゾリン誘導体及びその製法
JPH0673025A (ja) * 1992-06-26 1994-03-15 Zeneca Ltd キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
WO1995015758A1 (en) * 1993-12-10 1995-06-15 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase
WO1997030035A1 (en) * 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1998010767A2 (en) * 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
JP2002516823A (ja) * 1998-05-28 2002-06-11 パーカー ヒューズ インスティテュート 脳腫瘍の治療のためのキナゾリン
JP2002521475A (ja) * 1998-07-30 2002-07-16 パーカー ヒューズ インスティテュート 脂質を低下するキナゾリン誘導体
JP2002523403A (ja) * 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
JP2002539262A (ja) * 1999-03-19 2002-11-19 パーカー ヒューズ インスティテュート キナゾリン化合物製剤および治療におけるその使用
JP2002540103A (ja) * 1999-03-19 2002-11-26 パーカー ヒューズ インスティテュート キナゾリン類およびそれらの治療上における使用方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007191430A (ja) * 2006-01-19 2007-08-02 Fujifilm Ri Pharma Co Ltd ４−フェノキシキナゾリン誘導体放射性化合物
JP2011508752A (ja) * 2008-01-03 2011-03-17 コミッサリア ア ロンネルジー アトミック エ オ ゾンネルジー ザルテルナティーフ マークされたプリン誘導体の製造方法、該プリン誘導体、およびその使用
US11298432B2 (en) 2008-01-03 2022-04-12 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for preparing a marked purine derivative, said derivative and uses thereof

Also Published As

Publication number Publication date
US6126917A (en) 2000-10-03
EP1180034A1 (en) 2002-02-20
EP1180034A4 (en) 2003-05-14
IL146805A0 (en) 2002-07-25
WO2000072849A1 (en) 2000-12-07
CA2375826A1 (en) 2000-12-07
AU4857400A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
US6126917A (en) Epidermal growth factor receptor binding compounds for positron emission tomography
JP2004525919A (ja) 上皮増殖因子受容体チロシンキナーゼの放射能標識された不可逆的阻害剤ならびに放射線画像化および放射線治療におけるその使用
Bonasera et al. Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase
Mishani et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors
JP7622113B2 (ja) Ｐｓｍａ阻害剤を含有する１８ｆ標識トリアゾール
Slobbe et al. Development of [18F] afatinib as new TKI-PET tracer for EGFR positive tumors
AU2002236194A1 (en) Radiolabeled Irreversible Inhibitors of Epidermal Growth Factor Receptor Tyrosine Kinase and Their Use in Radioimaging and Radiotherapy
Shaul et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer
US9107964B2 (en) Radioactive fluorine-labeled compound
US20060025430A1 (en) Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis
Huang et al. Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma
BRPI0808503B1 (pt) Composto, uso de um composto, e, composição farmacêutica
VanBrocklin et al. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes
CN1893944B (zh) 具有抗增殖活性的3-氰基喹啉衍生物
AU2013254326B2 (en) Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
JP5404405B2 (ja) 組織低酸素症の非侵襲的検出用の弱塩基性２−ニトロイミダゾール
JP2007505101A (ja) 放射性標識されたアニリノキナゾリン型化合物ならびに放射線画像化および放射線治療におけるその使用
ES2237447T3 (es) Derivado de nitroimidazol y agente de diagnostico formador de imagenes que lo contiene.
US20210009624A1 (en) [18f] fmau labeling for pet imaging of cancer patients
JP2016511754A (ja) 放射性標識キナゾリン誘導体
Garcia et al. A quinazoline-derivative DOTA-type gallium (III) complex for targeting epidermal growth factor receptors: synthesis, characterisation and biological studies
US20080138282A1 (en) Radiolabeled Arylsulfonyl Compounds and Uses Thereof
JP2009161477A (ja) 腫瘍イメージング剤
Riese Dialkoxyquinazolines: Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes
HK1207852B (en) Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110422